Autolus Therapeutics plc

AUTL • Biotechnology

$2.24

▼ -0.05 (-2.18%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$596.20M

Growth

45.2%

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 92.0%Healthy liquidity · 5.94Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:11 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.24

Change-2.18%

Shares Out266.16M

Market Cap$596.20M

Enterprise Value$478.08M

52W Range1.18 - 2.43

Beta2.02

P/E-2.13

P/S5.08

P/B7.97

P/FCF-2.55

EV/Sales4.07

Price$2.24

Change-2.18%

Shares Out266.16M

Market Cap$596.20M

Enterprise Value$478.08M

52W Range1.18 - 2.43

Beta2.02

P/E-2.13

P/S5.08

P/B7.97

P/FCF-2.55

EV/Sales4.07

EV/EBITDA-2.03

EV/FCF-2.04

Earnings Yield-46.97%

FCF Yield-39.22%

Dividend Yield0.00%

Gross Margin-27.83%

Oper. Margin-3.72%

Profit Margin-3.81%

Debt/Eq1.97

Current Ratio5.94

Quick Ratio5.48

Revenue 5Y45.17%

Target$8.87

Target Upside295.98%

Target Median$8.00

Target Range7.60 - 11.00

Volume3.88M

Avg Volume1.56M

EPS Surprise0.02

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

58/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

62/100

Why this score▼

Positive revenue growth · 92.0%Healthy liquidity · 5.94Weak profitability

Analyst view

Analyst sentiment and price target

AUTL

Analyst sentiment

Based on 14 analyst votes · 2026-09-05

89/100

Bullish

Hold

Bearish

Price Target

2026-08-13

Low

$7.60

Mean

$8.87

Median

$8.00

High

$11.00

Company Overview

IPO: 6/22/2018

Industry: Biotechnology

P/B i: 7.97

Debt / Equity i: 1.97

Operating Margin: -372.45%

Net Margin: -381.40%

ROE i: -

ROIC: -

Financial Health

Score12 / 20

Debt / Equity: 1.97

Current Ratio: 5.94

Quick Ratio: 5.48

Status: Good

Insider Transactions

Recent executive and insider activity

BONNEY MICHAEL W

Transaction: 06/29/2026

BUY

Change

+31,667

Price

Not reported

Filing

07/01/2026

Type

BUY

BONNEY MICHAEL W

Transaction: 06/29/2026

BUY

Change

+47,500

Price

$1.61

Filing

07/01/2026

Type

BUY

Azelby Robert

Transaction: 06/29/2026

BUY

Change

+31,667

Price

Not reported

Filing

07/01/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
BONNEY MICHAEL W	BUY	+31,667	Not reported	06/29/2026	07/01/2026
BONNEY MICHAEL W	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Azelby Robert	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Azelby Robert	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Bain Linda	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Bain Linda	BUY	+47,500	$1.61	06/29/2026	07/01/2026
BUTITTA CYNTHIA M	BUY	+31,667	Not reported	06/29/2026	07/01/2026
BUTITTA CYNTHIA M	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Iannone Robert	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Iannone Robert	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Leiderman Elisabeth	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Leiderman Elisabeth	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Richardson Ryan	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Richardson Ryan	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Rao Madduri Ravin	BUY	+31,667	Not reported	06/29/2026	07/01/2026
Rao Madduri Ravin	BUY	+47,500	$1.61	06/29/2026	07/01/2026
YOUNG WILLIAM D	BUY	+31,667	Not reported	06/29/2026	07/01/2026
YOUNG WILLIAM D	BUY	+47,500	$1.61	06/29/2026	07/01/2026
Richardson Ryan	OTHER	+80,000	$1.41	03/18/2026	03/23/2026
Neville Miranda Suzette	OTHER	+83,300	Not reported	03/18/2026	03/18/2026

About the Company

Autolus Therapeutics plc

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Source - link

Peers

ADCT ANNX AURA BNTC LBRX NMRA QSI RAPT RCKT SLDB

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript

Seeking Alpha

Autolus Therapeutics Q2 Earnings Call Highlights

Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.

MarketBeat

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026.

GlobeNewsWire

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 million Capital base strengthened through five-year, interest-only credit facility with $75 million funded at close Autolus to report Q2 2026 financial results on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date.

GlobeNewsWire

Autolus Therapeutics: Navigating A Bumpy 2026

Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis and multiple sclerosis represents significant long-term upside, with pivotal data expected in 2027–2028 and a potentially underserved market niche. Despite modest revenue growth and a positive gross margin, AUTL faces a short cash runway, relying on restructuring and sales growth to extend liquidity into Q4 2027.

Seeking Alpha

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-0.29	-0.27	0.02
2026-03-27	-0.25993	-0.34	-0.08007
2025-11-12	-0.23	-0.3	-0.07
2025-08-12	-0.24	-0.18	0.06
2025-05-08	-0.24	-0.26	-0.02
2025-03-20	-0.21	-0.09	0.12
2024-11-12	-0.21	-0.31	-0.1
2024-08-08	-0.19	-0.22	-0.03
2024-05-17	-0.1	-0.24	-0.14
2024-03-14	-0.26	-0.44	-0.18
2023-11-02	-0.24	-0.26	-0.02
2023-08-03	-0.22	-0.26	-0.04